Search: onr:"swepub:oai:gup.ub.gu.se/49287" >
Tumor necrosis fact...
Tumor necrosis factor gene polymorphism and cardiac allograft vasculopathy
-
- Ternström, Lisa, 1972 (author)
- Gothenburg University,Göteborgs universitet,Hjärt-kärlinstitutionen,Cardiovascular Institute
-
- Jeppsson, Anders, 1960 (author)
- Gothenburg University,Göteborgs universitet,Hjärt-kärlinstitutionen,Cardiovascular Institute
-
- Ricksten, Anne, 1957 (author)
- Gothenburg University,Göteborgs universitet,Institutionen för laboratoriemedicin, Avdelningen för klinisk kemi/transfusionsmedicin,Institute of Laboratory Medicine, Dept of Clinical Chemistry/Transfusion Medicine
-
show more...
-
- Nilsson, Folke, 1950 (author)
- Gothenburg University,Göteborgs universitet,Hjärt-kärlinstitutionen,Cardiovascular Institute
-
show less...
-
(creator_code:org_t)
- 2005
- 2005
- English.
-
In: J Heart Lung Transplant. - 1053-2498. ; 24:4, s. 433-8
- Related links:
-
https://gup.ub.gu.se...
Abstract
Subject headings
Close
- BACKGROUND: Cardiac allograft vasculopathy (CAV) limits survival after cardiac transplantation. Tumor necrosis factor-alpha (TNF-alpha) may be a key factor in the development of CAV. Two bi-allelic polymorphisms associated with high TNF-alpha production have been identified in the TNF gene locus, TNFA1/2, at position -308 and TNFB1/2 at +252. We hypothesized that recipient TNFA2 and TNFB2 homozygosity is associated with the development of CAV after heart transplantation. METHODS: TNF gene polymorphisms were analyzed by multiplex fluorescent solid-phase mini-sequencing in 70 cardiac transplant recipients. Recipients homozygous for TNFA2 or TNFB2 (Group A, n = 29) were compared with recipients heterozygous or homozygous for TNFA1 and TNFB1 (Group B, n = 41). Coronary arteriography was performed annually or when indicated. Cumulative freedom from CAV and survival was calculated according to the Kaplan-Meier test. RESULTS: Mean follow-up was 3.8 +/- 0.3 years. In Group A, 11 of 29 recipients (38%) developed CAV compared with 9 of 41 (22%) in Group B (p = 0.12). Cumulative freedom from CAV at 3 years was 42% in Group A and 80% in Group B (p = 0.043). In Group A, 11 of 29 recipients (38%) died during follow-up compared with 4 of 41 (10%) in Group B (p = 0.006). Cumulative survival at 3 years was 72% in Group A and 93% in Group B (p = 0.003). CONCLUSIONS: The results suggest that TNFA2 and TNFB2 allele homozygosity is associated with cardiac allograft vasculopathy and mortality in heart transplant recipients.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Kirurgi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Surgery (hsv//eng)
Keyword
- Adult
- Coronary Angiography
- Coronary Arteriosclerosis/*blood/etiology/radiography
- Coronary Vessels/*pathology
- Female
- Follow-Up Studies
- Gene Frequency
- Genetic Markers
- Graft Rejection/blood/prevention & control
- Graft Survival/genetics
- Heart Transplantation/*adverse effects/mortality
- Humans
- Immunosuppressive Agents/therapeutic use
- Male
- Middle Aged
- Polymerase Chain Reaction
- *Polymorphism
- Genetic
- Prospective Studies
- Survival Rate
- Transplantation
- Homologous
- Tumor Necrosis Factor-alpha/biosynthesis/*genetics
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
To the university's database